Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

4D Pharma Plc ADR (LBPS)

4D Pharma Plc ADR (LBPS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,114
  • Shares Outstanding, K 16,433
  • Annual Sales, $ 720 K
  • Annual Income, $ -31,940 K
  • 60-Month Beta 0.71
  • Price/Sales 50.54
  • Price/Cash Flow N/A
  • Price/Book 1.15
Trade LBPS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5000 +10.00%
on 06/22/22
3.4200 -51.75%
on 05/27/22
-1.5500 (-48.44%)
since 05/24/22
3-Month
1.5000 +10.00%
on 06/22/22
5.5000 -70.00%
on 03/25/22
-3.7700 (-69.56%)
since 03/24/22
52-Week
1.5000 +10.00%
on 06/22/22
11.0933 -85.13%
on 06/25/21
-9.5100 (-85.22%)
since 06/24/21

Most Recent Stories

More News
4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq

4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that...

DDDD.LN : 16.660 (+5.04%)
LBPS : 1.6500 (+2.48%)
Update on Suspension of Trading

4D pharma plc (AIM: DDDD, Nasdaq: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (+5.04%)
4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced the...

DDDD.LN : 16.660 (+5.04%)
LBPS : 1.6500 (+2.48%)
4D pharma to Present at the H.C. Wainwright Global Investment Conference

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (+5.04%)
4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (+5.04%)
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (+5.04%)
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer

Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor...

ONCY : 1.0042 (+1.18%)
ONC.TO : 1.31 (+0.77%)
SPPI : 0.8030 (-5.51%)
LBPS : 1.6500 (+2.48%)
REVB : 0.6257 (+27.05%)
CELZ : 0.6944 (+1.55%)
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

ZTEK and FMAC are leading our lists this morning

HSTO : 2.33 (+3.10%)
ALLG : 5.11 (-9.72%)
ZTEK : 1.7300 (-3.89%)
LBPS : 1.6500 (+2.48%)
CREX : 0.6200 (unch)
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (+5.04%)
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (+5.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

4D pharma plc is a pharmaceutical company. It involved in the development of Live Biotherapeutic products a novel class of drug derived from the microbiome. 4D pharma plc, formerly known as Longevity Acquisition Corporation, is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 1.7033
2nd Resistance Point 1.6767
1st Resistance Point 1.6633
Last Price 1.6500
1st Support Level 1.6233
2nd Support Level 1.5967
3rd Support Level 1.5833

See More

52-Week High 11.0933
Fibonacci 61.8% 7.4287
Fibonacci 50% 6.2966
Fibonacci 38.2% 5.1646
Last Price 1.6500
52-Week Low 1.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar